MetaCap

OnKure Therapeutics (OKUR) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

OnKure Therapeutics (OKUR) has outperformed Spruce Biosciences (SPRB) over the past year, gaining 4.7% versus a loss of 63.8%. Over five years, OKUR leads with a -96.2% price change compared with -99.8% for SPRB. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $109.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OKUR+4.65%SPRB-63.81%
+113%+20%-72%
Nov 21, 20251 yearNov 20, 2026
OKUR-96.62%SPRB-99.77%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OKUR versus SPRB key metrics
MetricOKURSPRB
Share price$2.70$38.00
Market cap$111.21M$109.21M
1-day change-2.17%-6.15%
YTD return-6.90%-56.38%
1-year return+4.65%-63.81%
5-year return-96.16%-99.75%
Forward P/E—11.79
EPS (TTM)$-2.26$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Revenue growth (YoY)—-100.00%
Net income (latest FY)$-59.52M$-38.97M
52-week high$5.38$111.00
52-week low$2.01$38.00
Distance from 52-week high-49.81%-65.77%
Analyst consensusnonestrong_buy
Avg. price target upside+464.81%+288.00%
Average volume335.78K89.33K
Shares outstanding40.50M2.87M
Employees4525
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OKUR has outperformed SPRB by 68.5 percentage points over the past year.

About OnKure Therapeutics

OKUR stock →

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

OKUR vs SPRB FAQ

Which is bigger, OnKure Therapeutics or Spruce Biosciences?

OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $109.21M for Spruce Biosciences (SPRB).

Which stock has performed better over the past year, OKUR or SPRB?

OKUR returned +4.65% over the past 12 months, compared with -63.81% for SPRB (price return, excluding dividends). Past performance does not predict future results.

Are OnKure Therapeutics and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons